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Abstract
Background: In the present study, we describe heterodimerization between human-Somatostatin Receptor 5
(hSSTR5) and b2-Adrenergic Receptor (b2AR) and its impact on the receptor trafficking, coupling to adenylyl cyclase
and signaling including mitogen activated protein kinases and calcineurin-NFAT pathways.
Methods: We used co-immunoprecipitation, photobleaching- fluorescence resonance energy transfer and
Fluorescence assisted cell sorting analysis to characterize heterodimerization between SSTR5 and b2AR.
Results: Our results indicate that hSSTR5/b2AR exist as preformed heterodimers in the basal condition which is
enhanced upon co-activation of both receptors. In contrast, the activation of individual receptors leads to the
dissociation of heterodimers. Receptor coupling to adenylyl cyclase displayed predominant effect of b2AR, however,
somatostatin mediated inhibition of cAMP was enhanced upon blocking b2AR. Our results indicate hSSTR5
mediated significant activation of ERK1/2 and inhibition of phospho-p38. The phospho-NFAT level was enhanced in
cotransfected cells indicating the blockade of calcineurin mediated dephosphorylation of NFAT upon receptor
heterodimerization.
Conclusion: These data for the first time unveil a novel insight for the role of hSSTR5/b2AR in the modulation of
signaling pathways which has not been addressed earlier.
Keywords: G-protein-coupled receptor, Human somatostatin receptor-5, β2 adrenergic receptors, Heterodimeriza-
tion, Photobleaching-fluorescence resonance energy transfer and Somatostatin
Background
We have recently described homo-and heterodimeriza-
tion of somatostatin receptor (SSTR) subtypes and its
functional consequences on receptor trafficking and sig-
naling in response to agonist activation. SSTRs heterodi-
merization is not restricted to its own family but has
also been demonstrated with other member of G-pro-
tein coupled receptors (GPCRs) family such as dopa-
mine and opioid receptors as well as with the members
of receptor tyrosine kinase family [1-4]. In several
pathological conditions including neurodegenerative dis-
eases and tumors of different origin, somatostatin (SST)
via its five receptor subtypes plays crucial role and
serves as an important therapeutic approach. Most
recent example of clinical implication of heterodimeriza-
tion is the development of chimeric molecules of
hSSTR5 and dopamine receptor 2 in treatment of pitui-
tary tumor [5,6].
Adrenergic receptors (ARs) specifically b1AR and
b2AR are the prominent receptor subtypes from GPCR
family and have provided first convincing evidence in
support of GPCRs dimerization [7-13]. b1AR and b2AR
exhibit some similarities, but also exert receptor specific
role on signaling molecules including receptor depen-
dent stimulation of apoptosis and mitogen activated
protein kinases (MAPKs). Widespread distributions of
AR subtypes in different tissues provide the broad spec-
trum of physiological importance specifically in cardiac
physiology [10,14-17]. However, the direct mechanistic
and physiological importance of the ARs in heart failure * Correspondence: ujkumar@mail.ubc.ca
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transgenic mice [16-19].
SSTR subtypes are also well expressed in cardiac tis-
sues and have been attributed to the beneficial role in
cardiac physiology and are associated with positive and
negative contractile function in concentration dependent
manner [20-22]. Most importantly in patients with pitui-
tary tumor (acromegaly) and Huntington’s disease (HD),
the high mortality rate is associated with cardiovascular
diseases [23]. These significant observations anticipate
the possibility of functional interaction between SSTR
and b-AR subtypes. SSTRs and b-ARs have been studied
extensively for homo-and heterodimerization within the
family and with dopamine and opioid receptors with
physiological significance and clinical implications
[2,4,8,13,24-30]. There is no direct evidence whether
SSTR and b-AR subtypes functionally interact with each
other. Although, as early as in 1985, a study has
described that in rat brain astrocytes, SST enhanced the
production of b-AR mediated cyclic adenosine mono-
phosphate (cAMP) [31]. In addition, agonist occupied b-
AR gets phosphorylated in presence of b-AR kinase and
SST and isoproterenol displayed similar effect in pro-
moting the translocation of b-AR kinase [32,33].
Recently, we have shown the distributional pattern and
colocalization of SSTRs and b-ARs in H9c2 cells [34]. In
addition, we have described the functional interaction
between SSTR5 and b1AR in human embryonic kidney
cells (HEK-293 cells) [35]. These studies further support
our concept and are compelling evidences to predict the
functional interaction between adrenergic and somatos-
tatin receptors in a receptor specific manner.
Accordingly, in the present study by using morpholo-
gical, biochemical and biophysical techniques, we stu-
died the heterodimerization between Gi-coupled
hSSTR5 and Gs-coupled b2AR in HEK-293 stably
cotransfected with both receptors and compared with
monotransfected cells. We also analyzed receptor traf-
ficking, coupling to adenylyl cyclase and downstream
signaling cascades including extracellular signal-regu-
lated kinases (ERK1/2), p38, protein kinase A (PKA) and
nuclear transcriptional factor (NFAT) in mono-and/or
cotransfected cells. Our results showed that hSSTR5/
b2AR exhibits heterodimerization in basal condition or
upon combined activation and modulate signaling path-
ways in receptor specific manner.
Materials and methods
Materials
Somatostatin-14 was obtained from Bachem, Torrance,
CA. b2AR agonist formoterol hemifumarate and antago-
nist ICI-118551 was purchased from Tocris Cookson
Inc., Ellisville, Missouri, USA. The non-peptide agonist
L-817818 (hSSTR5) was provided by Dr. S.P. Rohrer
from Merck & Co [36]. Monoclonal and polyclonal anti-
bodies against HA- and cMyc- and b-actin were pro-
cured from Sigma-Aldrich, Inc., St. Louis, MO.
Fluorescein and rhodamine conjugated goat-anti-mouse
and goat-anti-rabbit secondary antibodies were pur-
chased from Jackson Immuno Research ON. Polyclonal
antibodies for total and phospho-ERK1/2 (phosphoryla-
tion site-Thr202/Tyr204) and p38 (phosphorylation site-
Thr180/Tyr182) were obtained from Cell Signaling
Technology, Danvers, MA. Antibodies for total and
phospho-PKA (phosphorylation site-Thr198) and NFAT
(phosphorylation site-Ser265) were purchased from
Santa Cruz Biotechnology, Santa Cruz, CA. cAMP assay
k i tw a sp u r c h a s e df r o mB i o V i s i o n ,I n c .C A ,U S A .P r o -
tein A/G-Agarose beads were procured from Calbio-
chem, EMD Biosciences, Darmstadt, Germany. Reagents
for electrophoresis were purchased from BIO-RAD
Laboratories Mississauga ON, Canada. 4’,6-diamidino-2-
phenylindole (DAPI) dihydrochloride was purchased
from Molecular Probes, Inc., Eugene, OR. Reagents for
cell culture were purchased from GIBCO, Invitrogen,
B u r l i n g t o n ,O N ,C a n a d a .O t h e rr e a g e n t sw e r eo fA R
grade and were procured from various sources.
Receptor Constructs and Cell Lines
cMyc-b2AR in pCDNA3.1
+/Hygro vector (hygromycin
resistance) was purchased from TOP Gene Technolo-
gies, Montreal, Canada. Construct of HA-SSTR5 was
made using the pCDNA3.1
+/Neo (neomycin resistance)
as previously described [2,24,25,37]. The stable transfec-
tions of HA-hSSTR5 and cMyc- b2AR in HEK-293 cells
were prepared by Lipofectamine transfection reagent as
described [1,2,24,25,37]. Cotransfection of cMyc-b2AR
in the HEK-293 cells stably expressing HA-hSSTR5 was
performed using Lipofectamine transfection reagent and
the cells were maintained in Dulbecco’sM E Ms u p p l e -
mented with 10% fetal bovine serum (FBS), 700 μg/ml
neomycin and 400 μg/ml hygromycin as described ear-
lier [1,2,24,25,37].
Co-immunoprecipitation (Co-IP)
HEK-293 cells cotransfected with cMyc-b2AR/HA-
hSSTR5 were treated with SST (1 μM) and formoterol
(1 μM) alone or in combination for 30 min at 37°C.
Membrane protein (250 μg) was solubilized in 1 ml of
radioimmune precipitation assay buffer (RIPA Buffer,
150 mM NaCl, 50 mM Tris-HCL, 1% Nonidet P-40,
0.1% SDS, 0.5% sodium deoxycholate, pH 8.0) for 1 h
at 4°C and Co-IP was performed as previously
described [35]. Briefly, samples were incubated with 1
μg antibody overnight at 4°C. 25 μlo fp r o t e i nA / G -
agarose beads were added to immunoprecipitate anti-
body for 2 h at 4°C. Beads were washed and solubilized
in Laemmli sample buffer (Bio-Rad) and fractionated
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The fractionated proteins were transferred to a 0.2 μm
nitrocellulose membrane and blotted with anti-HA or
anti-cMyc antibody (dilution 1:500) for the expression
of HA-hSSTR5 and cMyc-b2AR and detected by che-
miluminescence using ECL Western blotting detection
kit (Amersham) according to the manufacturer’s
instructions [24,37]. Images were captured using an
Alpha Innotech FluorChem 8800 gel box imager
(Alpha Innotech Co., San Leandro, CA).
Photobleaching- Fluorescence Resonance Energy Transfer
(Pb-FRET) Microscopic Analysis
HEK-293 cells expressing cMyc- b2AR/HA-hSSTR5
were grown on poly-D-lysine coated glass coverslips to
60-70% cell confluency. Cells were treated with 1 μM
SST and 1 μM b2 agonist alone or in combination for
15 min at 37°C and fixed with 4% paraformaldehyde for
20 min on ice and were further processed for immuno-
fluorescence immunocytochemistry [24,35,37]. Monoclo-
nal anti-HA and polyclonal anti-cMyc primary
antibodies were used followed by FITC- and Cy3- con-
jugated secondary antibodies to create donor-acceptor
pair. The plasma membrane region was used to analyze
the photobleaching decay on a pixel-by-pixel basis as
previously described [24,37]. The FRET efficiency (E)
was calculated in terms of a percent based upon the
photo bleaching (Pb) time constants of the donor taken
in the absence (D-A) and presence (D+A) of acceptor
and relative FRET efficiency was calculated as previously
described [35].
Receptor Internalization
To study receptor internalization, HEK-293 cells stably
expressing cMyc-b2AR/HA-hSSTR5 were grown on
poly-D-Lysine coated coverslips to 60-70% cell con-
fluency. Cells were treated with SST (1 μM) and formo-
terol (1 μM) alone or in combination for 15 min at 37°C
and were processed for immunocytochemistry as pre-
viously described [25,35,37]. Receptor expression in both
non-permeabilized and permeabilized cells was analyzed
by using Leica DMLB microscope attached with the
Retiga 2000R camera. DAPI dihydrochloride was used
for nuclear staining. Adobe Photoshop was used to con-
struct figure composites and merged images displaying
colocalization were generated by using Image J software,
NIH.
Fluorescence assisted cell sorting (FACS) Analysis
The changes in cell surface expression of receptors and
measurement of FRET was also performed by using a
FACS. Approximately 2 × 10
6 cells were treated with
SST, formoterol and CGP alone or in combination for
15 min at 37 C in DMEM. Cells were washed with
FACS buffer (PBS pH7.4, 5% FBS, 2 mM EDTA), fixed
in 4% paraformaldehyde and were processed for immu-
nostaining. Anti-HA and anti-cMyc primary antibodies
were used followed by FITC- and Cy3- fluorescence
conjugated secondary antibodies. Non-stained cells were
used to setup the background level of fluorescence
whereas; control cells stained with either Cy3- or FITC-
was used as fluorescence control. A BD LSRII flow cyt-
ometer, configured with a 488 nm and 561 nm laser
was used for the experiments. The level of Cy3- was
monitored using the 561 nm laser and a 610/20 emis-
sion filter to directly measure the b2AR expression
levels. The cells were excited with the 488 nm laser first
and the emission was detected using a 530/30 filter to
detect the SSTR5 expression level whereas a 610/20 fil-
ter was used to detect any Cy3 emission due to FRET
between SSTR5 and b2AR. Data analysis was done by
using FlowJo 7.6 software.
Receptor Coupling to Adenylyl Cyclase (AC)
Briefly, to determine the basal levels of cAMP, trans-
fected cells were incubated for 30 min with receptor
specific agonists alone or in combination at 37°C in pre-
sence of 0.5 mM 3-isobutyl-1-methylxanthine. Similarly,
cells were also incubated for 30 min with receptor speci-
fic agonist alone or in combination at 37°C in presence
of 20 μM forskolin (FSK) and 0.5 mM 3-isobutyl-1-
methylxanthine. Control and treated cells were then
scraped in 0.1 N HCl and cAMP was determined by
immunoassay using a cAMP Kit from BioVision, Inc.
CA, USA according to the manufacturer’sg u i d e l i n e s
[24,37].
To determine the G-proteins coupling with b2AR and
SSTR5 in mono- and/or cotransfected cells, G-Protein
antagonizing peptide (GPAP) or Melittin and Pertussis
toxin (PTX) were used to inhibit Gs and Gi respectively.
Mono-and cotransfected HEK-293 cells expressing
cMyc-b2AR and/or HA-hSSTR5 were grown in 6 well
culture plates and used at > 70% cell confluency for
cAMP assay [37]. In addition to the receptor specific
agonist/antagonists, cells were also treated with GPAP
(5 μM) and Melittin (1 μM) for 2 h and PTX (100 ng/
ml) for 16-18 h in DMEM at 37°C and processed for
cAMP estimation.
Western blot analysis
HEK-293 cells monotransfected with b2AR or hSSTR5
were treated with receptor specific agonist whereas cells
coexpressing b2AR/hSSTR5 were treated with SST (1
μM), L-817818 (10 nM) and formoterol (1 μM) alone or
in combination for 10 min and 30 min at 37°C. Whole
cell lysate prepared from cells were fractionated via
SDS-PAGE and transferred to a 0.2 μM nitrocellulose
membrane. Immunoblotting for ERK1/2 and p38 were
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fic antibodies and the bands were quantified by densito-
metry using FluorChem software as described earlier
[35]. b-actin was used as loading control.
To determine the expression of total- and phospho-
PKA and NFAT, mono- and/or cotransfected HEK-293
cells were treated with 1 μM SST, 10 nM L-817818, 1
μM formoterol alone or in combination for 10 or 30
min at 37°C in the medium containing 1.8 mM or 2.5
mM Ca
2+. Cells were further processed and western blot
was performed accordingly as described earlier [24,37].
Statistical Analysis
Results are presented as mean ± S.E unless otherwise
stated. Statistical analysis was carried out using Graph
Pad Prism 4.0 and statistical differences were taken at p
values < 0.05. The results presented here represent three
independent experiments.
Results
Human somatostatin receptor 5 and b2 adrenergic
receptor are constitutive heterodimers
To ascertain whether b2AR and hSSTR5 exists as hetero-
dimers, we first determined heterodimerization using Co-
IP in stably cotransfected HEK-293 cells. Membrane pre-
paration from control and treated cells were immunopre-
cipitated for cMyc-b2AR and probed with antibody
directed against HA to recognize HA-hSSTR5. As shown
in Figure 1A, upon treatment with SST and formoterol
alone or in combination, a band at ~110 kDa, the expected
size of HA-hSSTR5/cMyc-b2AR heteromeric complex was
detected in cMyc immunoprecipitate. To further confirm
the specificity of the blot, same membrane was striped and
reprobed with the anti-cMyc antibody to determine the
expression of cMyc-b2AR. As shown in Figure 1B, mono-
mers and homodimers of b2AR as well as heterodimers of
hSSTR5/b2AR were observed at the expected molecular
s i z eo f~ 6 0k D a ,~ 1 3 0k D aa n d~ 1 1 0k D ar e s p e c t i v e l y .
The immunoprecipitate prepared from hSSTR5 or b2AR
monotransfected cells probed reciprocally were devoid of
any heteromeric complex (Figure 1C and 1D).
Microscopic Photobleaching Fluorescence resonance
energy transfer (Pb-FRET)
Heterodimerization between hSSTR5/b2AR as seen in
Co-IP assay was further confirmed by microscopic Pb-
FRET analysis (Figure 2A and 2B). Cells were processed
for receptor expression by using monoclonal anti-HA
and polyclonal anti-cMyc antibodies followed by FITC-
(donor) and Cy3- (acceptor) conjugated secondary anti-
bodies. Cells expressing HA-hSSTR5 and cMyc-b2AR
displayed relative FRET efficiency of 10 ± 0.5%, indicating
that hSSTR5/b2AR exists as preformed heterodimers at
basal condition (Figure 2A and 3A). Interestingly, upon
treatment with SST or formoterol alone, cells displayed
3.7 ± 1.3% and 4.2 ± 1.1% of relative FRET efficiency
respectively in comparison to control. However, co-acti-
vation of hSSTR5 and b2AR exhibited 17.4 ± 1% of rela-
tive FRET efficiency, significantly higher than the basal
level (Figure 2B and 3A). These data suggest that the
simultaneous activation of both the receptors enhanced
the formation of heteromeric complex between hSSTR5
and b2AR. Similar results were observed when directly
labeled HA- and cMyc- antibodies were used in FRET
analysis to support that FRET signals were not due to the
aggregation of antibodies (data not shown).
Fluorescence resonance energy transfer analysis by using
FACS
To further confirm the results obtained from Co-IP and
microscopic Pb-FRET analysis, non-invasive, sensitive
and quantitative FACS analysis was employed to deter-
mine the receptor heterodimerization in cotransfected
cells. Cells were processed as described in Materials and
methods. To measure the FRET between SSTR5 and
b2AR, Cy3- emission at 610/20 was detected upon exci-
tation of FITC with 488 nm laser in double labeled cells
(Figure 3B-D). As shown in the Figure 3B, no significant
emission in 610/20 channel was detected when Cy3
labeled cells were excited with 488 nm laser (mean
fluorescence intensity = 21.1). In contrast, when both
the receptors were labeled with fluorescence conjugated
antibodies, excitation with 488 laser in control resulted
in the enhanced emission at 610/20 channel displaying
mean fluorescence of 26.2, indicating FRET (Figure 3C).
Upon treatment with receptors specific agonist alone,
cells displayed mean fluorescence comparable to Cy3
labeled cells (~22.0). Interestingly, upon combined ago-
nist treatment, increased FRET was observed with
enhanced mean fluorescence of 28.8 indicating fostered
heterodimerization (Figure 3D). Taken in consideration,
these data indicate that heterodimerization observed
between SSTR5 and b2AR by using Co-IP, Pb-FRET and
FACS analysis is receptor specific.
Receptor and agonist dependent internalization of
hSSTR5 and b2AR using indirect immunofluorescence and
FACS analysis
Previous studies have shown that hSSTR5 and b2AR dis-
played internalization upon agonist treatment [28,38].
Here, we determined the expression pattern of hSSTR5
and b2AR at the cell surface and intracellularly in cotrans-
fected cells following treatment with the receptor specific
agonists by using indirect immunofluorescence micro-
scopy and FACS analysis. In control cells, hSSTR5 and
b2AR exhibited strong colocalization at the cell surface
than intracellularly (Figure 4A). Three different receptor
populations were detected intracellularly i.e., either
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membrane expression was decreased upon treatment with
SST and resulted in the loss of receptor colocalization at
the cell surface. Increased expression of hSSTR5 was
observed intracellularly without any significant effect on
b2AR membrane expression (Figure 4A). In contrast, upon
treatment with formoterol, b2AR internalized and resulted
with the loss of receptor expression at cell surface. This
resulted in the loss of colocalization with SSTR5 and
increased intracellular expression of b2AR (Figure 4A).
Importantly, simultaneous activation of both receptors dis-
played no significant changes in the membrane or intracel-
lular expression as well as in colocalization when
compared to the control.
Figure 1 Heterodimerization of hSSTR5 and b2AR in cotransfected HEK-293 cells. Mono-and/or cotransfected cells were treated as
indicated for 30 min at 37°C. A single band at the expected size of ~110 kDa an indicative of b2AR/hSSTR5 heterodimers was observed in b2AR
immunoprecipitate (arrow panel A). Same membrane was reprobed for b2AR expression using anti-cMyc specific antibody for the specificity of
heterodimers (arrow panel B). A band at the expected size of ~50 kDa was also seen for b2AR monomers. For specificity, monotransfected cells
expressing SSTR5 or b2AR were used. No bands at the expected molecular weights were observed in either control or treated condition
indicating the specificity of heterodimerization (Panels C and D). Data are representative of three independent experiments.
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further confirmed by using FACS analysis (Figure 4B, a-
h). In control cells, both the receptors were well
expressed on the membrane (Figure 4B, a and 4b). As
shown in panel c, a significant decrease in the SSTR5
expression (FITC intensity) upon treatment with SST
was observed, without any change in b2AR expression
(d). Upon treatment with formoterol, b2AR expression
(Cy3 intensity) was reduced (f), whereas, SSTR5 expres-
sion remained unaffected (e). In combined treatment
with both the agonist, no significant change in the emis-
sion at 530/30 and 610/20 filters was observed in com-
parison to control (Figure 4B, g and 4h). Taken
together, results from immunofluorescence and FACS
analysis indicate that agonist induced internalization of
b2AR and SSTR5 is receptor specific and is independent
of each other.
Inactivation of b2 AR is required for the inhibition of
cAMP via hSSTR5
To better understand the molecular mechanism of this
interaction, we first determined the changes in receptor
coupling to AC in mono and/or cotransfected cells. In
basal condition, cells transfected with b2AR showed rela-
tively higher cAMP formation (2.99 ± 0.2 picomole/mg
protein) in comparison to the cells transfected with
hSSTR5 (1.3 ± 0.3 picomole/mg protein) (Figure 5A). In
the presence of FSK, cells expressing b2AR or hSSTR5 dis-
played 7.9 ± 0.3 and 5.07 ± 0.41 picomole/mg protein of
cAMP respectively. Monotransfected cells expressing
hSSTR5 displayed inhibition of FSK stimulated cAMP
levels by 55 ± 3% and 54 ± 3% upon treatment with
SST and hSSTR5 specific agonist (L-817818) respectively
(Figure 5A). In contrast, level of cAMP increased by ~3
folds (8.23 ± 0.5 picomole/mg protein) in b2AR
Figure 2 Microscopic Pb-FRET analysis in HEK-293 cells coexpressing cMyc-b2AR/HA-hSSTR5. (A) Representative photomicrographs of
HEK-293 cells illustrating cMyc-b2AR (red), HA-hSSTR5 (green) and colocalization in merged image (yellow) (Panel a). Pb-FRET microscopy on
HEK-293 cells coexpressing cMyc-b2AR/HA-hSSTR5 was performed as described in Material and Methods. A selection of photomicrographs
illustrating photobleaching profile of donor alone and in the presence of acceptor are shown in panels b and d. Histograms shown in panels c
and e represents pixel by pixel analysis of time constant of donor and donor + acceptor and the mean time constant shown in black was
calculated from a Gaussian distribution curve. Note the increased time constant of donor in presence of acceptor, indicating interactions
between cMyc-b2AR/HA-hSSTR5. (B) HEK-293 cells expressing cMyc-b2AR/HA-hSSTR5 were treated with SST (1 μM) and formoterol (1 μM) in
combination for 15 min at 37°C. Activation of hSSTR5 with SST and b2AR with formoterol simultaneously displayed increase in the effective FRET
efficiency. Representative photomicrographs illustrating bleaching profile of the donor in the absence or presence of acceptor are shown in
panels b and d. Histograms shown in panels c and e represent pixel by pixel analysis of time constant of the donor alone or donor +
acceptor respectively in cells treated with SST and b2AR specific agonist together for 15 min. Data are representative of three independent
experiments performed in duplicate. Approximately 60-70 cells were analyzed per experiment.
Somvanshi et al. Journal of Molecular Signaling 2011, 6:9
http://www.jmolecularsignaling.com/content/6/1/9
Page 6 of 17monotransfected cells upon formoterol treatment. In
cotransfected cells, the basal intracellular cAMP level (1.65
± 0.2 picomole/mg protein) was elevated by ~4 folds in
the presence of formoterol (8.4 ± 0.4 picomole/mg pro-
tein) (Figure 5B). Upon treatment with SST or L-817818,
FSK stimulated cAMP was inhibited by 8.6 ± 0.3% and 9 ±
1.5% respectively. Conversely, following treatment with
formoterol, FSK stimulated cAMP was increased by 6 ±
1%. Upon combined treatment with SST or L-817818 and
formoterol cells displayed 7 ± 0.5% and 8.6 ± 1% increased
cAMP in the presence of FSK. Most importantly, blockade
of b2AR with receptor specific antagonist ICI-118551 (5
nM) in presence of SST resulted in enhanced inhibition of
FSK stimulated cAMP levels by 23 ± 1.6% (Figure 5C).
These data suggest that blockade of b2AR is essential for
the inhibitory role of SST in cotransfected cells.
Identification of G-Proteins involved in receptor coupling
GPCR coupling to AC is regulated by different G pro-
teins including Gs,G i,G q and G12 that play determi-
nant role on intracellular cAMP levels. b-ARs typically
interact with Gs whereas SSTRs have been shown to
Figure 3 Histogram and photomicrographs illustrating relative FRET efficiencies and FACS analysis in HEK-293 cells cotransfected with
hSSTR5 and b2AR. (A) Activation of hSSTR5 with SST or b2AR with formoterol displayed decrease in the FRET efficiency indicating the
dissociation of receptor complex upon activation of individual receptors. In contrast, upon combined treatment with SST (1 μM) and formoterol
(1 μM), cells displayed enhanced heterodimerization. Mean ± S.E. are representative of three independent experiments performed in duplicate.
Data analysis was done by using ANOVA and post hoc Bonferroni’s Multiple Comparison test to compare with control and treated conditions. (B-
D) Approximately 2 × 10
6 cells were treated with receptor specific agonist as indicated in materials and methods section. Cells were washed
with FACS buffer, fixed in 4% paraformaldehyde and were processed for immunostaining as described. BD LSRII flow cytometer, configured with
a 488 nm and 561 nm laser was used for the experiments. Cy3 labeled cells were used as control (Panel B). Note the increased emission in 610/
20 channel when cells were excited with 488 nm laser in control (Panel C) as well as upon combined agonist treatment (Panel D).
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laboratory and others have described that b1AR/b2AR
also couple to Gi and activate signaling pathways in
distinct manner than Gs[17,39]. To ascertain the speci-
ficity of G proteins involved in b2AR and SSTR5
mediated regulation of cAMP, we used Gs inhibitors
GPAP and Melittin and Gi inhibitor PTX [40-42].
Mono and/or cotransfected cells were treated with
GPAP, Melittin and PTX as described in methods sec-
tion. As shown in Figure 6A, cells expressing b2AR
displayed increased levels of cAMP by ~125% in pre-
sence of FSK or formoterol, the effect which was
completely abrogated upon treatment with GPAP and
Melittin. b2AR stimulated cAMP was not affected in
presence of PTX in monotransfected cells (Figure 6A).
SST mediated effect on cAMP inhibition was comple-
tely abrogated upon PTX treatment in SSTR5 mono-
transfected cells, whereas, GPAP and Melittin had no
significant effect on cAMP levels (Figure 6A). These
data in concurrence with previous studies indicate that
b2AR and SSTR5 are coupled to Gs and Gi respectively
[17,43]. In cotransfected cells, increased level of cAMP
upon treatment with formoterol was abolished in pre-
sence of Gs inhibitors GPAP and Melittin but not with
Figure 4 Representative photomicrographs and FACS analysis illustrating receptor and agonist dependent internalization.( A) The cells
displayed colocalization at the membrane in non-permeabilized and intracellularly in permeabilized cells with distinct populations of hSSTR5
(green) and b2AR (red). Following treatment with SST, b2AR remain unchanged while hSSTR5 displayed agonist induced internalization. Upon
activation with formoterol, b2AR internalized as indicated by the loss of b2AR and colocalization with hSSTR5 at cell surface which is
accompanied with the increased intracellular expression. Combined treatment with SST and formoterol displayed colocalization between hSSTR5
and b2AR. In all representative photographs DAPI in blue color indicates nuclear staining. Scale bar = 10 μm. (B) BD LSRII flow cytometer
configured with a 488 nm and 561 nm laser was used for the experiments. Cy3- (b2AR expression, panels b, d, f and h) was monitored using
the 561 nm laser and a 610/20 emission filter whereas 488 nm laser was used to detect SSTR5 expression (FITC, panels a, c, e and g) and the
emission was detected using a 530/30 filter. Cells were processed as described in materials and methods section. Note the left side shifts in the
FITC and Cy3 expression (Panels c and f) indicating agonist dependent receptor specific internalization. No significant change in the expression
pattern for the receptors was observed upon combined activation with both the ligands (Panels g and h).
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presence of b2AR antagonist ICI was blocked with
PTX (Figure 6B). Interestingly, SST displayed inhibi-
tion of cAMP by 25% and 27% in the presence of
GPAP and Melittin respectively. These observations
indicate that b2AR is predominantly coupled to Gs in
monotransfected as well as in cotransfected cells
whereas, SSTR5 mediated regulation of cAMP is
mediated by Gi protein.
Differential regulation of Protein kinase A by hSSTR5 and
b2AR
Previous studies have suggested the critical role of PKA
in switching of G protein coupling of b2AR [44]. PKA
Figure 5 Inactivation of b2AR enhanced hSSTR5 coupling to adenylyl cyclase. Mono-and/or cotransfected HEK-293 cells were processed as
described in materials and methods. In basal condition, cAMP level was relatively higher in cells expressing b2AR (Panel A) in comparison to
hSSTR5 expressing cells (Panel A). However, both the cell lines displayed increased cAMP in the presence of FSK. As shown, SSTR5 transfected
cells exhibited the inhibition of cAMP in presence of SST and SSTR5 specific agonist. In cotransfected cells, basal level of cAMP was comparable
to hSSTR5 expressing cells (Panel B). Note the significant decrease in cAMP with SST in presence of b2AR antagonist (Panel C). Mean ± S.E. are
representative of three independent experiments performed in triplicate. Data analysis was done by using ANOVA and post hoc Dunnett’st o
compare against basal level (*, p < 0.01).
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inal domains which in turn promotes switching of
receptor coupling from Gs to Gi, thus activating differ-
ent signaling cascade [44]. To activate cAMP/PKA path-
way mono-and/or cotransfected cells were grown in
presence of basal Ca
2+ (1.8 mM) as well as in high con-
centration of Ca
2+ (2.5 mM) and cells were processed to
determine the status of PKA phosphorylation. As shown
in Figure 7A and 7B, b2AR or hSSTR5 monotransfected
cells displayed receptor and agonist specific changes on
PKA phosphorylation in presence of basal Ca
2+.I n
b2AR monotransfected cells, formoterol decreased PKA
phosphorylation upon 10 and 30 min treatment in com-
parison to control. In contrast, cells expressing hSSTR5
Figure 6 Specificity of G protein coupling. Mono-and cotransfected cells were treated with Gs inhibitors GPAP (5 μM) and Melittin (1 μM) for
2 h; 100 ng/ml PTX (Gi inhibitor) for 16-18 h in DMEM at 37°C and processed for cAMP estimation. GPAP and Melittin resulted in complete loss
of formoterol induced cAMP levels, whereas PTX had no significant effect on increased cAMP levels upon formoterol treatment in mono and/or
cotransfected cells (Panels A and B). In contrast regulation of cAMP levels by SSTR5 were completely abrogated upon PTX treatment in mono
or cotransfected cells. Mean ± S.E. are representative of three independent experiments performed in triplicate. Data analysis was done by using
ANOVA and post hoc Dunnett’s to compare against basal level (*, p < 0.05; **, p < 0.01).
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in presence of SST at 10 min, whereas upon 30 min
treatment phospho-PKA was comparable to control. In
cotransfected cells, PKA phosphorylation was decreased
upon 10 min treatment with formoterol alone or in
combination with SST or SSTR5 agonist in comparison
to control. However, following treatment for 30 min, the
level of phospho-PKA was decreased significantly in
comparison to control (Figure 7B). These results suggest
that in cotransfected cells, b2AR mediated inhibition of
phospho-PKA was predominant.
In comparison, at high Ca
2+ concentration in culture
medium, the level of phospho-PKA increased in cells
expressing b2AR and decreased in hSSTR5 transfected
cells when compared to basal Ca
2+ concentration. SST or
formoterol caused decrease in PKA phosphorylation in
monotransfected cells (Figure 7C). However, cotransfected
cells displayed complete inhibition of phospho-PKA upon
treatment with SST, L-817818 (SSTR5 agonist) and for-
moterol alone or in combination. The effect observed in
presence of high Ca
2+ indicates the blockade of cAMP/
PKA mediated pathway with predominant role of b2AR.
Figure 7 Time and receptor specific changes in PKA phosphorylation. To determine the expression levels of total and phospho-PKA, mono-
and cotransfected cells were treated with SST, L-817818 and formoterol alone or in combination for 10 and 30 min at 37°C in the presence of
basal (Panels A and B) and higher Ca
2+(Panel C). Upon 10 min treatment, cells expressing hSSTR5 displayed inhibition of PKA phosphorylation
in the presence of SST whereas no significant phosphorylation of PKA was detected in cells expressing b2AR. In cotransfected cells, b2AR effect
was predominant showing inhibition of pPKA with all treatments as indicated (Panel A). Interestingly, PKA phosphorylation was enhanced in
SSTR5 monotransfectant in control or in presence of SST for 30 min. With high Ca
2+ in culture medium, pPKA expression was higher in the
presence of b2AR in comparison to hSSTR5 and was inhibited upon activation of receptors respectively. In cotransfected cells, enhanced PKA
phosphorylation seen in monotransfected cells was completely diminished following agonist treatment (Panel C). Densitometric analysis of
western blot for pPKA is shown. Data analysis was done by using ANOVA and post hoc Dunnett’s to compare against basal level (*, p < 0.01).
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phosphorylation
The MAPK represents a critical signal transduction
cascade involved in multitude of cellular processes and
upon distinctive activation plays an important role in
responding to the growth and stress stimuli [45]. To
ascertain whether receptor heterodimerization and the
changes in cAMP/PKA regulate downstream signaling
cascades, we next examined the status of key MAPKs
i.e., ERK1/2 and p38 in mono-and cotransfected HEK-
293 cells. As shown in Figure 8A, the activation of
b2AR and hSSTR5 enhanced phosphorylation of ERK1/
2 in monotransfected cells. This effect was relatively
more pronounced in SSTR5 transfected cells following
treatment with SST for 10 and 30 min (Figure 8A and
8B). In comparison to monotransfectant, the cells
coexpressing both the receptors, ERK1/2 phosphoryla-
tion was receptor and time dependent with the promi-
nent effect of SST or SSTR5 agonist in combination
with formoterol upon 10 min treatment (Figure 8A
and 8B). In contrast, upon 30 min treatment with SST,
L-817818 and formoterol alone or in combination,
cells displayed decreased expression of phospho-ERK1/
2 in comparison to 10 min treatment (Figure 8B).
These results strongly support the Gi mediated activa-
tion of phospho-ERK1/2 at early time point (10 min)
whereas upon treatment for 30 min phospho-ERK1/2
is predominantly regulated by b2AR in heteromeric
Figure 8 Receptor mediated changes in ERK1/2 and p38 phosphorylation. Mono-and cotransfected HEK-293 cells were treated with SST (1
μM), L-817818 (10 nM) and formoterol (1 μM) alone or in combination at 37°C for 10 and 30 min (Panels A and B). In monotransfected cells,
increased expression of pERK1/2 was observed with more significant changes in SSTR5 expressing cells. Similar pattern was also seen following
30 min incubation albeit to the lesser degree. In comparison, cotransfected cells displayed discernable changes at 10 or 30 min treatments
(Panels A and B). Densitometric analysis of western blot is shown for ERK1/2 (Panels C and D). Data analysis was done by using ANOVA and
post hoc Dunnett’s to compare against basal level (*, p < 0.01). As shown in panels E and F, no significant expression of phosphorylated p38
was observed in mono-and/or cotransfected HEK-293 cells with or without treatment. Data are representative of three independent experiments.
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quantify changes in phospho-ERK1/2 expression is pre-
sented in Figure 8C and 8D.
Changes in p38 expression in cells expressing hSSTR5
and b2AR
Several previous studies have described that changes in the
p38 expression are associated with pro and/or anti-apop-
totic effects in receptor and tissue specific manner [45].
b2AR coupling to Gi has been appreciated for its role in
cell survival pathway due to anti-apoptotic action other
than Gs mediated signaling. In contrast, hSSTR5 is shown
to exert antiproliferative effects. Whether or not b2AR
encounter or potentiate this effect of hSSTR5 in cotrans-
fected cells is not known. Here, we examined the status of
phospho-p38 in mono-and cotransfected cells expressing
b2AR and hSSTR5. Monotransfected cells displayed weak
expression of phospho-p38 upon receptor specific activa-
tion at 10 min in comparison to control (Figure 8E). Fol-
lowing 30 min incubation in presence of receptor specific
agonists phosphorylated p38 was not detected despite the
expression of total p38 as indicated (Figure 8F). The phos-
pho-p38 was not detected in cotransfected cells with or
without receptor specific activation alone or in combina-
tion following 10 or 30 min treatments, whereas expres-
sion level of total p38 remained comparable in all the
conditions as indicated in Figure 8E and 8F.
The presence of b2AR and hSSTR5 regulates
dephosphorylation and nuclear translocation of NFAT
Calcium mediated activation of Calcineurin induces
dephosphorylation of NFAT transcription factor in the
cytoplasm and increased dephosphorylation persuade its
nuclear translocation which is associated with activation
of several gene expression [46]. Accordingly, in this
experiment we compared the expression of phospho-
NFAT in mono-and/or cotransfected HEK-293 cells. As
shown in Figure 9A, no significant changes in the
expression of pNFAT were observed when b2AR or
hSSTR5 monotransfected cells were treated with recep-
tor specific agonists in presence of basal Ca
2+.C o m p a r -
able expression of phospho-NFAT was observed in
Figure 9 hSSTR5 and b2AR blocks the dephosphorylation of NFAT. Mono-and cotransfected HEK-293 cells were treated with SST (1 μM), L-
817818 (10 nM), b2 agonist (1 μM) alone or in combination at 37°C for 30 min and analyzed for total and phosphorylated NFAT in presence of
basal and elevated Ca
2+. In the presence of basal Ca
2+ no significant changes were seen in NFAT phosphorylation in mono-and/or cotransfected
cells expressing b2AR or hSSTR5 (Panel A). In the presence of high Ca
2+ in culture medium, increased level of phosphorylated NFAT was
observed in monotransfected cells when compared with basal Ca
2+ control. Cotransfected cells displayed increased phospho-NFAT upon
formoterol treatment whereas NFAT phosphorylation remained comparable to control upon activation of SSTR5 alone or in combination with
b2AR agonist (Panel B). Densitometric analysis of western blot for pNFAT is shown in panels C and D. Data analysis was done by using ANOVA
and post hoc Dunnett’s to compare against control (*, p < 0.05).
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as treated conditions as indicated. However, the status
of NFAT phosphorylation was elevated in HEK-293 cells
expressing hSSTR5 or b2AR in presence of high Ca
2+
with no significant effect of receptor specific activation
(Figure 9B). In cotransfected cells, Formoterol treatment
enhanced the phosphorylation of NFAT significantly
whereas SST or L-817818 alone or in combination with
Formoterol the expression of phospho-NFAT was com-
parable to control. To quantify the changes in phospho-
NFAT expression, densitometric analysis was performed
(Figure 9C and 9D). These results provide direct evi-
dence that b2AR and hSSTR5 ablated calcineurin
mediated dephosphorylation and nuclear translocation
of NFAT.
Discussion
In the present study, we describe the heterodimerization
between b2AR and hSSTR5 in stably cotransfected
HEK-293 cells and characterized its role on key signal-
ing pathways. Our study showed that b2AR and hSSTR5
exist as preformed heterodimers in basal condition and
regulate receptor trafficking, coupling to AC and modu-
late the signaling cascades in receptor and time depen-
dent manner. Although, b2AR has been studied
extensively as a model of receptor dimerization, present
study revealed for the first time that b2AR and hSSTR5
can function synergistically on selective MAPKs and
cAMP dependent protein kinase A. Significantly, the
effects of SSTR5 in association with b2AR are comple-
tely different from the hSSTR5/b1AR heterodimers as
described recently [35].
The heterodimerization between chemokine receptor 4
and opioid receptor is stabilized in the presence of
ligands for both protomers whereas, the activation of
individual receptor prompted dissociation of heterodi-
meric complex and leads to the inactivation of signaling
pathway [47]. In agreement with these observations by
using conventional co-immunoprecipitation, microscopic
Pb-FRET and FACS analysis, here we describe that
b2AR/hSSTR5 exists as heterodimers in basal condition
and heterodimerization was disrupted upon activation of
b2AR or hSSTR5 alone. Devi et al., described that simul-
taneous activation of opioid receptor and b2AR
enhanced the heterodimerization [27]. Consistent with
these observations, we here describe that synergistic
activation of b2AR and hSSTR5 resulted in enhanced
heterodimerization while activation of individual recep-
tor was devoid of such effect [27]. Interestingly, this is
just opposite to our recent study demonstrating that co-
activation of hSSTR2/hSSTR5 is not required for hetero-
dimerization and the activation of single protomer is
fully capable to exhibit the formation of heterooligomers
[24]. Increased FRET efficiency upon activation of both
receptors suggests the changes in conformation and
orientation of receptor distribution at cell surface. In
contrast, the activation of single receptor prompted the
dissociation and resulted in loss of FRET efficiency.
Consistent with these observations, we have recently
shown the activation of individual receptor in cells
cotransfected with b1AR/hSSTR5 promotes the forma-
tion of homodimers preferentially over heterodimeriza-
tion of the receptors [35].
FACS is emerging as one of the most modern and
reliable technique for determining fluorescence reso-
nance energy transfer along with quantification of cell
surface expression of receptors. FACS is highly sensitive
and large number of cells live or fixed can be analyzed
in a short duration of time [48]. We took an advantage
of the versatility of FACS, and determined the FRET
between b2AR and hSSTR5 upon treatment with recep-
tor specific agonist alone or in combination. The FACS-
FRET is quantitative, highly accurate, reproducible
method and the results obtained further supports the
data procured from the classical method like Co-IP or
the state of art biophysical method Photobleaching-
FRET analysis.
Receptor heterodimerization at the cell surface serves
as regulatory mechanism for receptor expression and
receptor specific internalization in presence of specific
ligand [49-51]. As shown earlier, b2AR exhibits interna-
lization in agonist dependent manner whereas b1AR is
confined at the cell surface and impairs b2AR internali-
zation in b1AR/b2AR cotransfected cells [28]. SSTR sub-
types upon ligand induced activation displayed receptor
specific internalization in time and temperature depen-
dent manner except hSSTR1 that is rather upregulated
at cell surface and only internalize with hSSTR5 in het-
eromeric complex [38]. We have recently shown that
b1AR regulates internalization of hSSTR5 which displays
colocalization at the cell surface [35]. Here, we described
that cells cotransfected with b2AR and hSSTR5 exhibit
b2AR or SSTR5 internalization upon receptor specific
activation. Most importantly, synergistic activation of
both receptors exhibit strong colocalization at cell sur-
face and may account for enhanced FRET efficiency as
discussed above. Our results are consistent with pre-
vious study describing the receptor specific internaliza-
tion and trafficking of b2AR and δ or  opioid receptors
in heterodimeric complex [27].
All five human SSTR subtypes inhibit adenylyl cyclase-
cAMP via pertussis toxin-sensitive Gi proteins [37]. In
contrast, ARs are positive regulators of AC via coupling
to Gs [44]. However, b1AR and b2AR upon heterodimer-
ization display no significant changes in cAMP levels in
comparison to monotransfected cells [28]. Interestingly,
b2AR can also couple to Gi and inhibit AC activity [52].
In addition, selective activation of b2AR in the cells
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tion of ORs resulted in the inhibition of cAMP [27].
Our results strongly support the notion that presence of
both receptor subtypes exerts opposing effect in regula-
tion of cAMP with prominent role of b2AR upon com-
bined treatment. Most importantly, blockade of b2AR in
the presence of b2AR antagonist enhanced the inhibitory
role of SST on FSK stimulated cAMP. Our observations
implicate that inactivation of b2AR is the prerequisite to
unmask the SST mediated inhibitory role in regulation
of cAMP levels in cells cotransfected with b2AR and
SSTR5. These results are consistent with our previous
study describing the effect of b1AR and SSTR5 on
cAMP regulation although the inhibitory effect of SST
was more pronounced in b1AR/SSTR5 transfected cells
[35].
The activation of cAMP/PKA, MAPK and calcineurin
dependent NFAT dephosphorylation and nuclear trans-
location of NFAT are intimately associated events in
regulation of adrenergic receptor functions. PKA expres-
sion is suppressed upon activation of SSTRs suggesting
that cAMP/PKA is inhibited due to the activation of Gi.
Although, b2AR mediated activation of cAMP/PKA is
well established via coupling to Gs h o w e v e r ,t h er o l eo f
G proteins coupling in cotransfected cells has not been
studied in detail. The results described here indicate
that heterodimerization may not involve in promoting
switching of G protein Coupling. Further in addition,
previous studies have shown that b2AR coupling to dual
G proteins shifts towards Gi upon PKA mediated phos-
phorylation of b2ARs [44]. This transition from Gs to Gi
is most controversial and poorly understood and further
studies are required to resolve such discrepancies.
Recently, using Fluorescence fluctuations of quantum-
dot sensors report that b2AR agonist mediated PKA
activation is completed within 3s [53]. Whether pro-
longed activation of b2AR involved in this transition is
not known. Taken together, the time dependent changes
described here suggest that activation of PKA at early
time points might be sufficient enough to phosphorylate
b2AR to involve Gi mediated effect which may partially
recover upon 30 min. Most importantly, in cotransfected
cells, complete inhibition of PKA phosphorylation at
high Ca
2+ further strengthens the concept of Gi
mediated coupling of both the receptor subtypes. These
data strongly suggest the crucial role of hSSTR5/b2AR
heterodimerization is attributed to Gi mediated effect of
b2AR. The results presented here are significantly dis-
tinct from the b1AR/SSTR5 transfected cells, as the acti-
vation of SSTR5 enhanced PKA phosphorylation and
Isoproterenol treatment resulted in inhibition of PKA
phosphorylation in cotransfected cells [35].
In addition to receptor coupling to cAMP and PKA
phosphorylation, the changes in MAPKs including
phosphorylation of ERK1/2 and p38/JNK pathways have
been studied extensively as functional consequence of
GPCR activation and dimerization. In contractile cells,
Gi mediated activation of ERK via GPCRs has been
reported [54]. Consistent with these studies, b2AR inter-
nalization is associated with the inhibition of ERK phos-
phorylation [28]. Here, we describe the sustained
activation of ERK1/2 in cells expressing hSSTR5 and
b2AR upon synergistic activation of hSSTR5/b2AR. Such
activation of ERK directly correlates with receptor het-
erodimerization. Whether or not this effect of SSTR5 is
associated with anti-proliferative effect of SST via activa-
tion of ERK needs to be determined. Interestingly, the
effect of b1AR or b2AR agonist on the phosphorylation
of ERK1/2 has significantly diverse effects. As previously
shown, Isoproterenol treatment resulted in increased
phospho-ERK1/2 expression, whereas formoterol has
inhibitory effect on phosphorylation of ERK1/2 [35].
Consistent with the changes in ERK1/2, the loss of
p38 in cotransfected cells is governed with the promi-
nent role of hSSTR5. Taken together increased ERK1/2
and loss in p-p38 expression might implicate in inhibi-
tion of cell proliferation. An antagonist of p38
(SB203580) reduce the agonist induced hypertrophy and
reduced p38 signaling in the heart promote myocyte
growth through a mechanism involving enhanced calci-
neurin-NFAT signaling [45]. Thus, calcineurin-NFAT
and JNK signaling pathways crosstalk represents a criti-
cal mechanism that regulate cell physiology specifically
in cells of cardiac origin [46]. HEK-293 cells express cal-
cineurin endogenously and its inactivation inhibits
NFAT dephosphorylation and translocation to nucleus,
the process which is regulated by Ca
2+[55-57]. In case
of b1AR/hSSTR5 heterodimers, the dominant role of
SSTR5 was evident as b1AR activation resulted in loss
of pNFAT levels whereas SSTR5 displayed consistent
expression of pNFAT [35]. We here describe that upon
formation of b2AR/hSSTR5 heterodimers, NFAT depho-
sphorylation is blocked significantly and both the recep-
tors contribute equally to exert this effect. Increased
NFAT phosphorylation in cotransfected cells provides
the first evidence that b2AR/hSSTR5 heterodimers
blocks NFAT dephosphorylation and its nuclear
translocation.
Although, SSTR5 heterodimerizes with b1AR as well
as b2AR however, it exhibit distinct regulation of signal-
ing pathways in both the cases. In cells transfected with
b1AR/SSTR5, the role of SSTR5 in regulation of signal-
ing is predominant whereas in cells transfected with
b2AR/SSTR5, the effect of SSTR5 is synergistic. In con-
clusion, data presented here provides new insight for
the role of hSSTR5 and b2AR which might have physio-
logical significance and therapeutic implications in car-
diac physiology in pituitary tumor and Huntington
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changes in signaling pathways including cAMP, PKA,
ERK1/2 and NFAT in hSSTR5/b2AR complex are quite
interesting. Whether SSTRs and b-ARs colocalize in car-
diac tissue in vivo is largely elusive and further studies
are warranted prior to draw any conclusion for the role
of SSTRs and b-ARs in this direction.
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